Phase II Study of S-1 Plus Either Irinotecan or Docetaxel for Non-small Cell Lung Cancer Patients Treated with More Than Three Lines of Treatment
Cancer Research and Treatment 2011³â 43±Ç 4È£ p.212 ~ p.216
±è´Þ¿ë(Kim Dal-Yong) - University of Ulsan College of Medicine Department of Oncology
ÀÌ´ëÈ£(Lee Dae-Ho) - University of Ulsan College of Medicine Department of Oncology
Àå¼±ÁÖ(Jang Sun-Joo) - University of Ulsan College of Medicine Department of Oncology
±è»óÀ§(Kim Sang-We) - University of Ulsan College of Medicine Department of Oncology
(Suh Cheol-Won) - University of Ulsan College of Medicine Department of Oncology
ÀÌÁ¤½Å(Lee Jung-Shin) - University of Ulsan College of Medicine Department of Oncology
Abstract
Purpose: This study was designed to evaluate the efficacy of a combination treatment of S-1 plus either irinotecan or docetaxel for advanced/metastatic non-small cell lung cancer (NSCLC) patients who have already failed 3 or more lines of treatment.
Materials and Methods: This was a prospective single center phase II study. The eligible patients received S-1 40 mg/m2 twice a day orally on days 1 though 14 combined with irinotecan 150 mg/m2on D1 only or docetaxel 35 mg/m2 on D1 and D8. The treatment was repeated every 3 weeks until disease progression, unacceptable toxicity, or patient refusal. The choice between the two regimens was made at the discretion of the treating physician.
Results: A total of 14 patients participated in the study. There were 3 patients with squamous cell carcinoma, 9 with adenocarcinoma, and 2 with NSCLC, NOS. Eight of the patients were male. There were 8 patients with an Eastern Cooperative Oncology Group (ECOG) of 1, and 6 patients with an ECOG of 2. All the patients had already been treated with platinum-based chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitor therapy. Out of the 14 patients, 10 received irinotecan and S-1 and the other 4 received docetaxel and S-1. Twelve patients had also received pemetrexed. Disappointingly, there were no response from 2 patients with a stable disease, and therefore, as per the protocol, we stopped the study early. With a median follow-up time of 49 months, the median survival time was 5.6 months (95% confidence interval, 4.3 to 6.9 months).
Conclusion: S-1 containing doublets did not show activity in this population as a salvage treatment and further investigation cannot be recommended.
Å°¿öµå
Non-small-cell lung carcinoma, Salvage therapy, S-1, Irinotecan, Docetaxel
KMID :
0939920110430040212
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
Treatment with S-1 and either irinotecan or docetaxel did not yield efficacy in heavily-treated advanced NSCLC patients as fourth-line or further- line therapy, and so this treatment cannot be recommended.